Novigenix
17.1.2024 08:02:15 CET | ACCESS Newswire | Press release
GENEVA, SWITZERLAND / ACCESSWIRE / January 17, 2024 / With cancer projected to escalate to 29 million cases by 2040[1], Novigenix, a pioneer in AI healthcare solutions, is rewriting the rules of cancer care. Their newest innovation, LITOSeek™, is primed to reshape drug development, offering a transformative leap forward.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.Personalized Cancer Treatment: Breaking Barriers
Every cancer is as unique as the person it affects. Tumors are in continuous dynamic interplay with the patient's immune defenses and are adept at subverting and escaping immune control. Novigenix is on a mission to improve the cancer treatment landscape, leveraging advanced AI and RNA analysis from a routine blood draw to provide more precise insights into patient immune responses to cancer treatments, compared to conventional DNA liquid biopsies that evaluate tumor evolution through circulating tumor DNA (ctDNA). Insights into the precise dynamic of patient immune response thus pave the way for superior therapeutic discoveries in the field.
Empowering Biopharma: Unveiling LITOSeek™ at Precision Medicine World Conference
On January 24th at the Precision Medicine World Conference in Silicon Valley, Novigenix will debut LITOSeek™, a groundbreaking solution designed to expedite drug development for biopharma companies.
AI and RNA Analysis: Pioneering Healthcare Transformation
With a decade-long track record, Novigenix successfully launched Colox® blood test in Switzerland, powered by AI and RNA analysis to detect early-stage colon cancer, marking a significant departure from invasive colonoscopy procedures. By aggregating data from diverse colon cancer patients, Novigenix identified immune system biomarkers crucial for early-stage detection, enhancing treatment outcomes.
Dr. Brian Hashemi, Novigenix's CEO and Chairman, emphasized, "Our experience with Colox® underscores the potential of AI RNA analysis. Ongoing studies across various cancer types have fuelled our Knowledge Base to uncover comprehensive sets of biomarkers via liquid biopsy and AI RNA analysis. Our validated immunotherapy response biomarkers provide early prediction of patient response and we invite biopharma companies to leverage our platform for more efficient and effective drug development."
Professor Pedro Romero, M.D. Chief Medical & Scientific Officer of Novigenix, and Founding Chief Editor of the Journal of Immunotherapy of Cancer, highlights the importance of patient immune response in the development of novel therapies: "AI RNA analysis is poised to revolutionize healthcare, accelerating conventional experimental drug development with data-driven precision immune response prediction. By swiftly analyzing systemic immune responses, AI compresses analysis times, expediting traditional drug development and powering discovery of novel therapy targets."
A Team Dedicated to the Future of Cancer Care
With over 20 Ph.D.-level scientists focused on the development of the LITOSeek™ platform and advancing next-generation liquid biopsy solutions, Novigenix is pioneering precision immunology to help transform cancer treatment paradigms for better patient outcomes.
#Ends#
[1] https://canceratlas.cancer.org/the-burden/the-burden-of-cancer/
Contact Information
Edwin Shankar
edwin.shankar@leidar.com
SOURCE: Novigenix
To view this piece of content from stats.newswire.com, please give your consent at the top of this page.View the original press release on newswire.com.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Redington MD and Group CEO V.S. Hariharan Appointed to GTDC Executive Committee12.5.2026 15:00:00 CEST | Press release
GTDC appointed V.S. Hariharan, Managing Director and Group CEO of the Redington Group, to its Executive Committee (EC) to guide strategy and provide operational oversight. The EC advances the organization's mission to educate, advocate, and influence the tech industry on the evolving role of IT distribution worldwide. Mr. Hariharan leads Redington's $11.8 billion distribution and supply chain business across 40 markets. Redington continues to strengthen its role as a Technology Orchestrator, enabling seamless connections across the ecosystem to Unlock Next opportunities for partners. TAMPA, FL / ACCESS Newswire / May 12, 2026 / The Global Technology Distribution Council (GTDC), the world's largest consortium of technology distributors, named V.S. Hariharan, Managing Director and Group CEO of Redington Limited, to its Executive Committee. The committee provides operational oversight and helps guide GTDC's long-term strategy, advancing the organization's mission to strengthen distributio
Braiin Advances Proposed Acquisition of Home.cc with Valuation and Growth-Capital Components Totaling Approximately A$73 Million to Build AI-Native LivTech Platform for Residential Lifecycle Services, Targeting the $3+ Trillion Global Residential Lifecycle Services Market12.5.2026 14:15:00 CEST | Press release
Proposed acquisition would combine Home's embedded residential distribution, payments infrastructure and household-services platform with Braiin's AI, CXaaS and PropTech ecosystem MELBOURNE, AU AND LONDON, UK / ACCESS Newswire / May 12, 2026 / Braiin Limited (NASDAQ:BRAI) ("Braiin" or the "Company"), a global AI platform company delivering automation and predictive analytics across precision agriculture, customer experience and property technology, today announced that it has entered into a non-binding term sheet to advance its proposed acquisition of Home.cc ("Home"), a Living Technology ("LivTech") platform focused on embedded residential distribution, household service activation, payments and connected living infrastructure. Under the proposed structure, Braiin would acquire a 50.1% majority interest in Cumbria Capital Ltd, the parent company of Home.cc, through a share purchase to be satisfied by the issuance of Braiin equity securities. The non-binding term sheet contemplates a p
Polaris Renewable Energy Announces Approval of SO1 Agreement by FOMB12.5.2026 13:50:00 CEST | Press release
TORONTO, ON / ACCESS Newswire / May 12, 2026 / Polaris Renewable Energy Inc. (TSX:PIF) ("Polaris" or the "Company"), is pleased to announce that, on May 8, 2026, the Financial Oversight and Management Board of Puerto Rico ("FOMB") approved the Battery Energy Storage System ("BESS") Standard Offer Agreement ("SO1 Agreement"). The approval of the FOMB completes the three-steps approval process for the SO1 Agreement, following prior regulatory approvals obtained from the Puerto Rico Energy Bureau ("PREB") and the Governing Board of the Puerto Rico Electric Power Authority ("PREPA"). The SO1 Agreement is intended to be executed between PREPA and Polaris Power US, Inc ("PPUS"), a wholly owned subsidiary of Polaris. The SO1 Agreement forms part of the Puerto Rico Accelerated Storage Addition Program ("ASAP"), a strategic initiative aimed at strengthening grid reliability across the island through the deployment of utility-scale BESS co-located with existing generation facilities. Under this
Elixir Technologies Unveils Elixir Muse: The AI Writing Assistant Built for Total Data Privacy12.5.2026 13:00:00 CEST | Press release
Elixir's new writing assistant product delivers AI-powered drafting, revision, translation, validation, tone of voice and sentiment analysis, and compliance analysis - without storing, harvesting or training on user data. OJAI, CA / ACCESS Newswire / May 12, 2026 / Elixir Technologies today introduced Elixir Muse™, a privacy-first AI writing assistant that significantly minimizes the workload involved in drafting, editing, proofreading and translating text. Powered by Elixir Ai, the company's proprietary AI technology, Elixir Muse™ assists both writers and content creators improve the quality, clarity and consistency of their written content through advanced AI features - all while safeguarding the privacy of user data. Elixir Muse™ introduces a fundamentally different approach to AI-assisted document iteration: one where privacy and control are prioritized from the start, rather than being an afterthought. With user-friendly writing features and proven use cases, the product functions
Dubai Health and AGFA HealthCare Mark 20 Years of Collaboration Supporting Dubai's Healthcare System12.5.2026 11:30:00 CEST | Press release
Dubai Health and AGFA HealthCare have marked 20 years of collaboration supporting Dubai's healthcare system, reflecting a shared commitment to advancing integrated, patient-centered care. DUBAI, AE / ACCESS Newswire / May 12, 2026 / Over the past two decades, AGFA HealthCare has supported Dubai's healthcare system - most recently contributing to Dubai Health's integrated academic health system across care, learning, and research through a shared digital foundation. It enables clinicians access to critical information while maintaining data security, operational continuity, and patient confidentiality, and supports large-scale screening services in high-volume settings. The partnership has progressed from digitizing diagnostic imaging into a comprehensive enterprise imaging, analytics, and AI ecosystem that supports multiple clinical specialties, leadership decision-making, and population-scale healthcare services across Dubai Health's expanding network. Atif Al Braiki, Chief Digital an
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom